title: Mitoxantrone and cyclophosphamide combination chemotherapy for the treatment of various canine malignancies.
abstract: Thirteen dogs with histopathologically confirmed malignancies were treated with mitoxantrone and cyclophosphamide combination therapy. One to four doses were administered at 21-day intervals. Recombinant human granulocyte colony-stimulating factor was administered to ameliorate myelosuppression in dogs with neutrophil nadirs less than 1,000/microl. While the protocol appears to be safe for use in tumor-bearing dogs, an advantage over mitoxantrone single-agent protocols in terms of tumor response was not demonstrated in this initial pilot study.
authors.affiliation: Department of Veterinary Medicine and Surgery, University of Missouri-Columbia, 65211, USA.
authors.forename: C J
authors.initials: CJ
authors.lastname: Henry
authors.forename: M S
authors.initials: MS
authors.lastname: Buss
authors.forename: K A
authors.initials: KA
authors.lastname: Potter
authors.forename: K J
authors.initials: KJ
authors.lastname: Wardrop
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004359:Drug Therapy, Combination; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D008942:Mitoxantrone / Q000008:administration & dosage; D009369:Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide; D008942:Mitoxantrone